Next Generation

CNS Delivery

Transforming the delivery of restorative treatments for severe neurological disorders

Neurochase Delivery System
Neurochase is a leading biotechnology company focused exclusively on developing innovative devices and consulting services for targeted CNS drug delivery. We have developed a new pathway to deliver advanced, scalable solutions for neurodegenerative diseases and brain tumours currently impacting hundreds of millions of people worldwide.
Learn More
*Currently For investigational use only. Not approved for clinical use in any geography.

Effective

Our cannula enables the distribution volume to be shaped to match individual treatment volumes.
Learn More

Efficient

Minimises OR time with each cannula insertion and fixation circa 10-minutes. Minimises infusion procedure time with simultaneous infusions of up to eight cannulas per patient on the ward. Bedside removal of cannulas.
Learn More

Scaleable

Cost-effective procedures are driven by simultaneous infusions in awake patients.
Learn More
Please enter your name and email address if you would like to download our Brochure
Our Vision

To ensure the delivery of therapeutics directly to the brain is faster, more accurate and accessible to all

Find out more
How Neurochase Supports Successful Drug Delivery Trials
Neurochase founder, Prof. Steven Gill, and Chief Medical Officer, Dr. Neil Barua, explain why many therapies fail due to an inability to deliver treatments directly to targeted areas in the Central Nervous System. ​
​
Discover how the Neurochase CED System is uniquely designed to overcome these challenges.

Events

Neurochase will be attending the following events and we welcome anyone who wants to come and see us for a chat.

News & Articles

© 2025 Neurochase
Privacy Policy